New progress in the application of anti-vascular endothelial growth factor drugs in proliferative diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Ke Dandan ,  Sun Xufang

Department of Ophthalmology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China;

Corresponding author：

Sun Xufang, Email: sunxufang2016@163.com

Keywords：

Diabetic retinopathy; Angiogenesis inhibitors; Laser coagulation; Vitrectomy; Review

DOI：

10.3760/cma.j.cn511434-20200514-00214

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In the past, panretinal photocoagulation (PRP) and vitrectomy (PPV) were the main treatments for proliferative diabetic retinopathy (PDR). In recent years, anti-vascular endothelial growth factor (VEGF) drugs have been used more and more widely in PDR due to their advantages in rapidly subtracting new blood vessels, reducing leakage, and promoting the absorption of blood. The combination of anti-VEGF drugs and PRP in the treatment of PDR, especially high-risk PDR, can increase the rate of neovascularization and prevent some patients with mild to moderate vitreous hemorrhage from PPV. The application of anti-VEGF drugs during the perioperative period of PPV can also reduce bleeding during the operation, shorten the operation time, and reduce surgical complications. Although clinical studies have confirmed that anti-VEGF drugs can be used as an alternative treatment for PRP, most patients require multiple and long-term treatments, which increase the psychological and economic burden of patients. It is expected that the cost of anti-VEGF drugs and the development of long-acting dosage forms can be reduced and bring better efficacy and benefits to PDR patients in the future.

Citation： Ke Dandan, Sun Xufang. New progress in the application of anti-vascular endothelial growth factor drugs in proliferative diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2021, 37(2): 162-168. doi: 10.3760/cma.j.cn511434-20200514-00214 Copy

1.	Mcdonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy[J]. Ophthalmology, 1985, 92(3): 388-393. DOI: 10.1016/s0161-6420(85)34016-2.
2.	Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation[J]. Retina, 2011, 31(6): 1009-1027. DOI: 10.1097/IAE.0b013e318217d739.
3.	Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision[J]. Ophthalmology, 2003, 110(12): 2386-2394. DOI: 10.1016/j.ophtha.2003.05.008.
4.	Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease[J]. Prog Retin Eye Res, 2003, 22(1): 1-29. DOI: 10.1016/s1350-9462(02)00043-5.
5.	Carmeliet P. Mechanisms of angiogenesis and arteriogenesis[J]. Nat Med, 2000, 6(4): 389-395. DOI: 10.1038/74651.
6.	Izuta H, Matsunaga N, Shimazawa M, et al. Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body[J]. Mol Vis, 2010, 16: 130-136.
7.	Tolentino MJ, Mcleod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate[J]. Am J Ophthalmol, 2002, 133(3): 373-385. DOI: 10.1016/s0002-9394(01)01381-2.
8.	Cheung CM, Vania M, Ang M, et al. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy[J]. Mol Vis, 2012, 18: 830-837.
9.	Izuta H, Chikaraishi Y, Adachi T, et al. Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients[J]. Mol Vis, 2009, 15: 2663-2672.
10.	Kaštelan S, Orešković I, Bišćan F, et al. Inflammatory and angiogenic biomarkers in diabetic retinopathy[J/OL]. Biochem Med (Zagreb), 2020, 30(3): 030502[2020-08-05]. https://pubmed.ncbi.nlm.nih.gov/32774120. DOI: 10.11613/BM.2020.030502.
11.	Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients[J]. Graefe's Arch Clin Exp Ophthalmol, 2005, 243(1): 3-8. DOI: 10.1007/s00417-004-0950-7.
12.	Song S, Yu X, Zhang P, et al. Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy[J/OL]. J Diabetes Complications, 2020, 34(9): 107641[2020-05-30]. https://pubmed.ncbi.nlm.nih.gov/32605862/. DOI: 10.1016/j.jdiacomp.2020.107641.
13.	Ma Y, Zhang Y, Zhao T, et al. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab[J]. Am J Ophthalmol, 2012, 153(2): 307-313. DOI: 10.1016/j.ajo.2011.08.006.
14.	Zhang X, Wu J, Wu C, et al. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection[J/OL]. Diabetes Res Clin Pract, 2020, 162: 108083[2020-02-11]. https://pubmed.ncbi.nlm.nih.gov/32057965/. DOI: 10.1016/j.diabres.2020.108083.
15.	Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8[J]. Ophthalmology, 1981, 88(7): 583-600. DOI: 10.1016/S0161-6420(81)34978-1.
16.	Ishibazawa A, Nagaoka T, Yokota H, et al. Characteristics of retinal neovascularization in proliferative diabetic retinopathy imaged by optical coherence tomography angiography[J]. Invest Ophthalmol Vis Sci, 2016, 57(14): 6247-6255. DOI: 10.1167/iovs.16-20210.
17.	Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings[J]. Arch Ophthalmol, 2009, 127(2): 132-140. DOI: 10.1001/archophthalmol.2008.565.
18.	Preti RC, Ramirez LM, Monteiro ML, et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial[J]. Br J Ophthalmol, 2013, 97(7): 885-889. DOI: 10.1136/bjophthalmol-2012-302675.
19.	Flynn HJ, Chew EY, Simons BD, et al. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group[J]. Ophthalmology, 1992, 99(9): 1351-1357. DOI: 10.1016/s0161-6420(92)31779-8.
20.	Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
21.	Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression[J]. Arch Ophthalmol, 2012, 130(9): 1145-1152. DOI: 10.1001/archophthalmol.2012.1043.
22.	Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy[J]. Ophthalmology, 2015, 122(2): 367-374. DOI: 10.1016/j.ophtha.2014.08.048.
23.	Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
24.	Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy[J]. JAMA, 2015, 314(20): 2137-2146. DOI: 10.1001/jama.2015.15217.
25.	Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy[J]. JAMA Ophthalmology, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
26.	Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial[J]. Lancet, 2017, 389(10085): 2193-2203. DOI: 10.1016/S0140-6736(17)31193-5.
27.	Lin J, Chang JS, Smiddy WE. Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy[J]. Ophthalmology, 2016, 123(9): 1912-1918. DOI: 10.1016/j.ophtha.2016.05.037.
28.	Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy[J]. JAMA Ophthalmology, 2017, 135(6): 576-584. DOI: 10.1001/jamaophthalmol.2017.0837.
29.	Hutton DW, Stein JD, Glassman AR, et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmology, 2019, 137(12): 1-9. DOI: 10.1001/jamaophthalmol.2019.4284.
30.	李毅斌. 抗VEGF时代糖尿病视网膜病变治疗的策略和发展方向[J]. 眼科, 2019, 28(4): 245-248. DOI: 10.13281/j.cnki.issn.1004-4469.2019.04.002.Li YB. Management tactics of diabetic retinopathy in the anti-VEGF era and the future[J]. Ophthalmol CHN, 2019, 28(4): 245-248. DOI: 10.13281/j.cnki.issn.1004-4469.2019.04.002.
31.	Obeid A, Su D, Patel SN, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor[J]. Ophthalmology, 2019, 126(3): 407-413. DOI: 10.1016/j.ophtha.2018.07.027.
32.	Sun JK, Glassman AR, Beaulieu WT, et al. Rationale and application of the Protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy[J]. Ophthalmology, 2019, 126(1): 87-95. DOI: 10.1016/j.ophtha.2018.08.001.
33.	Mehanna C, Abdul Fattah M, Haddad S, et al. Anti-VEGF therapy for persistent neovascularization after complete panretinal photocoagulation in proliferative diabetic retinopathy[J]. Ophthalmology Retina, 2019, 3(6): 473-477. DOI: 10.1016/j.oret.2019.02.001.
34.	Figueira J, Silva R, Henriques J, et al. Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial[J]. Ophthalmologica, 2016, 235(1): 34-41. DOI: 10.1159/000442026.
35.	Figueira J, Fletcher E, Massin P, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study)[J]. Ophthalmology, 2018, 125(5): 691-700. DOI: 10.1016/j.ophtha.2017.12.008.
36.	Zhou AY, Zhou CJ, Yao J, et al. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy[J]. Int J Ophthalmol, 2016, 9(12): 1772-1778. DOI: 10.18240/ijo.2016.12.12.
37.	Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, et al. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial[J]. Ophthalmologica, 2013, 230(1): 1-8. DOI: 10.1159/000348605.
38.	Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy[J]. Retina, 2009, 29(4): 516-522. DOI: 10.1097/IAE.0b013e31819a5fc2.
39.	Filho JAR, Messias A, Almeida FPP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy[J/OL]. Acta Ophthalmologica, 2011, 89(7): e567-e572. https://doi.org/10.1111/j.1755-3768.2011.02184.x. DOI: 10.1111/j.1755-3768.2011.02184.x.
40.	Ferraz DA, Vasquez LM, Preti RC, et al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy[J]. Retina, 2015, 35(2): 280-287. DOI: 10.1097/IAE.0000000000000363.
41.	He F, Yu W. Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study[J]. Eye (Lond), 2020, 34(8): 1413-1418. DOI: 10.1038/s41433-019-0628-3.
42.	Ali W, Abbasi KZ, Raza A. Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy[J]. J Coll Physicians Surg Pak, 2018, 28(12): 923-927. DOI: 10.29271/jcpsp.2018.12.923.
43.	Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern®[J]. Ophthalmology, 2020, 127(1): P66-P145. DOI: 10.1016/j.ophtha.2019.09.025.
44.	Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J]. Diabetes Care, 2010, 33(11): 2399-2405. DOI: 10.2337/dc10-0493.
45.	Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
46.	Ishibashi T, Li X, Koh A, et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema[J]. Ophthalmology, 2015, 122(7): 1402-1415. DOI: 10.1016/j.ophtha.2015.02.006.
47.	Korobelnik J, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema[J]. Ophthalmology, 2014, 121(11): 2247-2254. DOI: 10.1016/j.ophtha.2014.05.006.
48.	Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2015, 122(10): 2044-2052. DOI: 10.1016/j.ophtha.2015.06.017.
49.	Mitchell P, Mcallister I, Larsen M, et al. Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies[J]. Ophthalmol Retina, 2018, 2(10): 988-996. DOI: 10.1016/j.oret.2018.02.011.
50.	Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab[J]. JAMA Ophthalmol, 2017, 135(6): 558-568. DOI: 10.1001/jamaophthalmol.2017.0821.
51.	Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema[J]. N Engl J Med, 2015, 372(13): 1193-1203. DOI: 10.1056/NEJMoa1414264.
52.	Li F, Zhang L, Wang Y, et al. One-year outcome of conbercept therapy for diabetic macular edema[J]. Curr Eye Res, 2017, 43(2): 218-223. DOI: 10.1080/02713683.2017.1379542.
53.	Xu Y, Rong A, Xu W, et al. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study[J/OL]. BMC Ophthalmol, 2017, 17(1): 158[2017-08-25]. https://link.springer.com/article/10.1186/s12886-017-0554-8?utm_source=other&utm_medium=other&utm_content=null&utm_campaign=BSCN_4_DD01_CN_CNKI. DOI: 10.1186/s12886-017-0554-8.
54.	Gupta OP, Weichel ED, Regillo CD, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy[J]. Ophthalmic Surg Lasers Imaging, 2007, 38(4): 270-275. DOI: 10.3928/15428877-20070701-01.
55.	Steel DH, Connor A, Habib MS, et al. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Br J Ophthalmology, 2010, 94(9): 1219-1225. DOI: 10.1136/bjo.2009.170126.
56.	Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage[J]. Retina, 2006, 26(3): 275-278. DOI: 10.1097/00006982-200603000-00004.
57.	Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage[J]. Retina, 2009, 29(8): 1134-1140. DOI: 10.1097/IAE.0b013e3181b094b7.
58.	Chelala E, Nehme J, El RH, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy[J]. Retina, 2018, 38(6): 1127-1133. DOI: 10.1097/IAE.0000000000001673.
59.	Parikh RN, Traband A, Kolomeyer AM, et al. Intravitreal bevacizumab for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2017, 176: 194-202. DOI: 10.1016/j.ajo.2017.01.010.
60.	Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2008, 92(2): 213-216. DOI: 10.1136/bjo.2007.127142.
61.	Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(6): 837-842. DOI: 10.1007/s00417-008-0774-y.
62.	Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial[J]. Ophthalmology, 2009, 116(10): 1943-1948. DOI: 10.1016/j.ophtha.2009.07.001.
63.	Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
64.	Di Lauro R, De Ruggiero P, Di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2010, 248(6): 785-791. DOI: 10.1007/s00417-010-1303-3.
65.	陈博, 张宪, 杨华静, 等. 严重PDR玻璃体切割术后雷珠单抗注射的效果观察[J]. 国际眼科杂志, 2016, 16(12): 2176-2179. DOI: 10.3980/j.issn.16725123.2016.12.02.Chen B, Zhang X, Yang HJ, et al. The effect of intravitreal ranibizumab after pars plana vitrectomy in severe proliferative diabetic retinopathy[J]. Int Eye Sci, 2016, 16(12): 2176-2179. DOI: 10.3980/j.issn.16725123.2016.12.02.
66.	Yeh P, Yang C, Lin Y, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy[J]. Retina, 2009, 29(6): 768-774. DOI: 10.1097/IAE.0b013e3181a3b7ef.
67.	李隽, 徐国兴. 玻璃体切除术前注射抗VEGF类药物治疗PDF的疗效及安全性的meta分析[J]. 国际眼科杂志, 2017, 17(8): 1446-1456. DOI: 10.3980/j.issn.1672-5123.2017.8.13.Li J, Xu GX. Efficacy and safety of adjuvant intravitreal injection of anti-vascular endothelial growth factors prior to vitrectomy in the treatment of proliferative diabetic retinopathy: a meta-analysis[J]. Int Eye Sci, 2017, 17(8): 1446-1456. DOI: 10.3980/j.issn.1672-5123.2017.8.13.
68.	Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy[J]. Ophthalmology, 2011, 118(11): 2218-2226. DOI: 10.1016/j.ophtha.2011.03.036.
69.	Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2015(8): CD008214[2015-08-07]. https://pubmed.ncbi.nlm.nih.gov/26250103/. DOI: 10.1002/14651858.CD008214.pub3.
70.	Zhang Z, Liu H, Hernandez-Da Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials[J]. Am J Ophthalmol, 2013, 156(1): 106-115. DOI: 10.1016/j.ajo.2013.02.008.
71.	梁泽玉, 陈松, 何广辉, 等. 术前及术中2次应用康柏西普辅助玻璃体切割术治疗增生型糖尿病视网膜病变的临床研究[J]. 眼科新进展, 2019, 39(2): 162-167.Liang ZY, Chen S, He GH, et al. Clinical observation of the application of conbercept preoperatively and intraoperatively assisted to the vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2019, 39(2): 162-167.
72.	Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2012, 96(4): 587-590. DOI: 10.1136/bjophthalmol-2011-301005.
73.	Wei Q, Zhang T, Jiang R, et al. Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy[J]. Invest Ophthalmol Vis Sci, 2017, 58(13): 5783-5791. DOI: 10.1167/iovs.17-22345.
74.	Russo A, Longo A, Avitabile T, et al. Incidence and risk factors for tractional macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy[J/OL]. J Clin Med, 2019, 8(11): 1960[2019-11-13]. https://pubmed.ncbi.nlm.nih.gov/31766241/. DOI: 10.3390/jcm8111960.
75.	延艳妮, 魏文斌, 周金琼. 增生性糖尿病视网膜病变围手术期抗VEGF药物使用时机的选择[J]. 国际眼科纵览, 2015, 39(5): 333-336. DOI: 10.3760/cma.j.issn.1673-5803.2015.05.008.Yan YN, Wei WB, Zhou JQ. The using timing of anti·vascular endothelial growth factor at perioperative period for proliferative diabetic retinopathy[J]. Int Rev Ophthalmol, 2015, 39(5): 333-336. DOI: 10.3760/cma.j.issn.1673-5803.2015.05.008.
76.	Hu Z, Su Y, Xie P, et al. OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection[J]. Graefe's Arch Clin Exp Ophthalmol, 2019, 257(8): 1611-1619. DOI: 10.1007/s00417-019-04315-0.
77.	冯超逸, 徐格致. 抗血管内皮生长因子药物在糖尿病视网膜病变围手术期的应用[J]. 中国眼耳鼻喉科杂志, 2015, 15(4): 254-257. DOI: 10.14166/j.issn.1671-2420.2015.04.008.Feng CY, Xu GZ. The application of anti-vascular endothelial growth factor drugs in the perioperative period of diabetic retinopathy[J]. Chin J Ophthalmol and Otorhinolaryngol, 2015, 15(4): 254-257. DOI: 10.14166/j.issn.1671-2420.2015.04.008.

1. Mcdonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy[J]. Ophthalmology, 1985, 92(3): 388-393. DOI: 10.1016/s0161-6420(85)34016-2.
2. Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation[J]. Retina, 2011, 31(6): 1009-1027. DOI: 10.1097/IAE.0b013e318217d739.
3. Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision[J]. Ophthalmology, 2003, 110(12): 2386-2394. DOI: 10.1016/j.ophtha.2003.05.008.
4. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease[J]. Prog Retin Eye Res, 2003, 22(1): 1-29. DOI: 10.1016/s1350-9462(02)00043-5.
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis[J]. Nat Med, 2000, 6(4): 389-395. DOI: 10.1038/74651.
6. Izuta H, Matsunaga N, Shimazawa M, et al. Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body[J]. Mol Vis, 2010, 16: 130-136.
7. Tolentino MJ, Mcleod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate[J]. Am J Ophthalmol, 2002, 133(3): 373-385. DOI: 10.1016/s0002-9394(01)01381-2.
8. Cheung CM, Vania M, Ang M, et al. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy[J]. Mol Vis, 2012, 18: 830-837.
9. Izuta H, Chikaraishi Y, Adachi T, et al. Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients[J]. Mol Vis, 2009, 15: 2663-2672.
10. Kaštelan S, Orešković I, Bišćan F, et al. Inflammatory and angiogenic biomarkers in diabetic retinopathy[J/OL]. Biochem Med (Zagreb), 2020, 30(3): 030502[2020-08-05]. https://pubmed.ncbi.nlm.nih.gov/32774120. DOI: 10.11613/BM.2020.030502.
11. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients[J]. Graefe's Arch Clin Exp Ophthalmol, 2005, 243(1): 3-8. DOI: 10.1007/s00417-004-0950-7.
12. Song S, Yu X, Zhang P, et al. Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy[J/OL]. J Diabetes Complications, 2020, 34(9): 107641[2020-05-30]. https://pubmed.ncbi.nlm.nih.gov/32605862/. DOI: 10.1016/j.jdiacomp.2020.107641.
13. Ma Y, Zhang Y, Zhao T, et al. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab[J]. Am J Ophthalmol, 2012, 153(2): 307-313. DOI: 10.1016/j.ajo.2011.08.006.
14. Zhang X, Wu J, Wu C, et al. Comparison of aqueous humor levels of PlGF and VEGF in proliferative diabetic retinopathy before and after intravitreal conbercept injection[J/OL]. Diabetes Res Clin Pract, 2020, 162: 108083[2020-02-11]. https://pubmed.ncbi.nlm.nih.gov/32057965/. DOI: 10.1016/j.diabres.2020.108083.
15. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8[J]. Ophthalmology, 1981, 88(7): 583-600. DOI: 10.1016/S0161-6420(81)34978-1.
16. Ishibazawa A, Nagaoka T, Yokota H, et al. Characteristics of retinal neovascularization in proliferative diabetic retinopathy imaged by optical coherence tomography angiography[J]. Invest Ophthalmol Vis Sci, 2016, 57(14): 6247-6255. DOI: 10.1167/iovs.16-20210.
17. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings[J]. Arch Ophthalmol, 2009, 127(2): 132-140. DOI: 10.1001/archophthalmol.2008.565.
18. Preti RC, Ramirez LM, Monteiro ML, et al. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial[J]. Br J Ophthalmol, 2013, 97(7): 885-889. DOI: 10.1136/bjophthalmol-2012-302675.
19. Flynn HJ, Chew EY, Simons BD, et al. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group[J]. Ophthalmology, 1992, 99(9): 1351-1357. DOI: 10.1016/s0161-6420(92)31779-8.
20. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
21. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression[J]. Arch Ophthalmol, 2012, 130(9): 1145-1152. DOI: 10.1001/archophthalmol.2012.1043.
22. Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy[J]. Ophthalmology, 2015, 122(2): 367-374. DOI: 10.1016/j.ophtha.2014.08.048.
23. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
24. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy[J]. JAMA, 2015, 314(20): 2137-2146. DOI: 10.1001/jama.2015.15217.
25. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy[J]. JAMA Ophthalmology, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
26. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial[J]. Lancet, 2017, 389(10085): 2193-2203. DOI: 10.1016/S0140-6736(17)31193-5.
27. Lin J, Chang JS, Smiddy WE. Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy[J]. Ophthalmology, 2016, 123(9): 1912-1918. DOI: 10.1016/j.ophtha.2016.05.037.
28. Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy[J]. JAMA Ophthalmology, 2017, 135(6): 576-584. DOI: 10.1001/jamaophthalmol.2017.0837.
29. Hutton DW, Stein JD, Glassman AR, et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmology, 2019, 137(12): 1-9. DOI: 10.1001/jamaophthalmol.2019.4284.
30. 李毅斌. 抗VEGF时代糖尿病视网膜病变治疗的策略和发展方向[J]. 眼科, 2019, 28(4): 245-248. DOI: 10.13281/j.cnki.issn.1004-4469.2019.04.002.Li YB. Management tactics of diabetic retinopathy in the anti-VEGF era and the future[J]. Ophthalmol CHN, 2019, 28(4): 245-248. DOI: 10.13281/j.cnki.issn.1004-4469.2019.04.002.
31. Obeid A, Su D, Patel SN, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor[J]. Ophthalmology, 2019, 126(3): 407-413. DOI: 10.1016/j.ophtha.2018.07.027.
32. Sun JK, Glassman AR, Beaulieu WT, et al. Rationale and application of the Protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy[J]. Ophthalmology, 2019, 126(1): 87-95. DOI: 10.1016/j.ophtha.2018.08.001.
33. Mehanna C, Abdul Fattah M, Haddad S, et al. Anti-VEGF therapy for persistent neovascularization after complete panretinal photocoagulation in proliferative diabetic retinopathy[J]. Ophthalmology Retina, 2019, 3(6): 473-477. DOI: 10.1016/j.oret.2019.02.001.
34. Figueira J, Silva R, Henriques J, et al. Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial[J]. Ophthalmologica, 2016, 235(1): 34-41. DOI: 10.1159/000442026.
35. Figueira J, Fletcher E, Massin P, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study)[J]. Ophthalmology, 2018, 125(5): 691-700. DOI: 10.1016/j.ophtha.2017.12.008.
36. Zhou AY, Zhou CJ, Yao J, et al. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy[J]. Int J Ophthalmol, 2016, 9(12): 1772-1778. DOI: 10.18240/ijo.2016.12.12.
37. Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, et al. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial[J]. Ophthalmologica, 2013, 230(1): 1-8. DOI: 10.1159/000348605.
38. Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy[J]. Retina, 2009, 29(4): 516-522. DOI: 10.1097/IAE.0b013e31819a5fc2.
39. Filho JAR, Messias A, Almeida FPP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy[J/OL]. Acta Ophthalmologica, 2011, 89(7): e567-e572. https://doi.org/10.1111/j.1755-3768.2011.02184.x. DOI: 10.1111/j.1755-3768.2011.02184.x.
40. Ferraz DA, Vasquez LM, Preti RC, et al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy[J]. Retina, 2015, 35(2): 280-287. DOI: 10.1097/IAE.0000000000000363.
41. He F, Yu W. Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study[J]. Eye (Lond), 2020, 34(8): 1413-1418. DOI: 10.1038/s41433-019-0628-3.
42. Ali W, Abbasi KZ, Raza A. Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy[J]. J Coll Physicians Surg Pak, 2018, 28(12): 923-927. DOI: 10.29271/jcpsp.2018.12.923.
43. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern®[J]. Ophthalmology, 2020, 127(1): P66-P145. DOI: 10.1016/j.ophtha.2019.09.025.
44. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase Ⅱ study[J]. Diabetes Care, 2010, 33(11): 2399-2405. DOI: 10.2337/dc10-0493.
45. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
46. Ishibashi T, Li X, Koh A, et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema[J]. Ophthalmology, 2015, 122(7): 1402-1415. DOI: 10.1016/j.ophtha.2015.02.006.
47. Korobelnik J, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema[J]. Ophthalmology, 2014, 121(11): 2247-2254. DOI: 10.1016/j.ophtha.2014.05.006.
48. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2015, 122(10): 2044-2052. DOI: 10.1016/j.ophtha.2015.06.017.
49. Mitchell P, Mcallister I, Larsen M, et al. Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies[J]. Ophthalmol Retina, 2018, 2(10): 988-996. DOI: 10.1016/j.oret.2018.02.011.
50. Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab[J]. JAMA Ophthalmol, 2017, 135(6): 558-568. DOI: 10.1001/jamaophthalmol.2017.0821.
51. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema[J]. N Engl J Med, 2015, 372(13): 1193-1203. DOI: 10.1056/NEJMoa1414264.
52. Li F, Zhang L, Wang Y, et al. One-year outcome of conbercept therapy for diabetic macular edema[J]. Curr Eye Res, 2017, 43(2): 218-223. DOI: 10.1080/02713683.2017.1379542.
53. Xu Y, Rong A, Xu W, et al. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study[J/OL]. BMC Ophthalmol, 2017, 17(1): 158[2017-08-25]. https://link.springer.com/article/10.1186/s12886-017-0554-8?utm_source=other&utm_medium=other&utm_content=null&utm_campaign=BSCN_4_DD01_CN_CNKI. DOI: 10.1186/s12886-017-0554-8.
54. Gupta OP, Weichel ED, Regillo CD, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy[J]. Ophthalmic Surg Lasers Imaging, 2007, 38(4): 270-275. DOI: 10.3928/15428877-20070701-01.
55. Steel DH, Connor A, Habib MS, et al. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Br J Ophthalmology, 2010, 94(9): 1219-1225. DOI: 10.1136/bjo.2009.170126.
56. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage[J]. Retina, 2006, 26(3): 275-278. DOI: 10.1097/00006982-200603000-00004.
57. Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage[J]. Retina, 2009, 29(8): 1134-1140. DOI: 10.1097/IAE.0b013e3181b094b7.
58. Chelala E, Nehme J, El RH, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy[J]. Retina, 2018, 38(6): 1127-1133. DOI: 10.1097/IAE.0000000000001673.
59. Parikh RN, Traband A, Kolomeyer AM, et al. Intravitreal bevacizumab for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2017, 176: 194-202. DOI: 10.1016/j.ajo.2017.01.010.
60. Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2008, 92(2): 213-216. DOI: 10.1136/bjo.2007.127142.
61. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(6): 837-842. DOI: 10.1007/s00417-008-0774-y.
62. Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial[J]. Ophthalmology, 2009, 116(10): 1943-1948. DOI: 10.1016/j.ophtha.2009.07.001.
63. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
64. Di Lauro R, De Ruggiero P, Di Lauro R, et al. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefe's Arch Clin Exp Ophthalmol, 2010, 248(6): 785-791. DOI: 10.1007/s00417-010-1303-3.
65. 陈博, 张宪, 杨华静, 等. 严重PDR玻璃体切割术后雷珠单抗注射的效果观察[J]. 国际眼科杂志, 2016, 16(12): 2176-2179. DOI: 10.3980/j.issn.16725123.2016.12.02.Chen B, Zhang X, Yang HJ, et al. The effect of intravitreal ranibizumab after pars plana vitrectomy in severe proliferative diabetic retinopathy[J]. Int Eye Sci, 2016, 16(12): 2176-2179. DOI: 10.3980/j.issn.16725123.2016.12.02.
66. Yeh P, Yang C, Lin Y, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy[J]. Retina, 2009, 29(6): 768-774. DOI: 10.1097/IAE.0b013e3181a3b7ef.
67. 李隽, 徐国兴. 玻璃体切除术前注射抗VEGF类药物治疗PDF的疗效及安全性的meta分析[J]. 国际眼科杂志, 2017, 17(8): 1446-1456. DOI: 10.3980/j.issn.1672-5123.2017.8.13.Li J, Xu GX. Efficacy and safety of adjuvant intravitreal injection of anti-vascular endothelial growth factors prior to vitrectomy in the treatment of proliferative diabetic retinopathy: a meta-analysis[J]. Int Eye Sci, 2017, 17(8): 1446-1456. DOI: 10.3980/j.issn.1672-5123.2017.8.13.
68. Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy[J]. Ophthalmology, 2011, 118(11): 2218-2226. DOI: 10.1016/j.ophtha.2011.03.036.
69. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2015(8): CD008214[2015-08-07]. https://pubmed.ncbi.nlm.nih.gov/26250103/. DOI: 10.1002/14651858.CD008214.pub3.
70. Zhang Z, Liu H, Hernandez-Da Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials[J]. Am J Ophthalmol, 2013, 156(1): 106-115. DOI: 10.1016/j.ajo.2013.02.008.
71. 梁泽玉, 陈松, 何广辉, 等. 术前及术中2次应用康柏西普辅助玻璃体切割术治疗增生型糖尿病视网膜病变的临床研究[J]. 眼科新进展, 2019, 39(2): 162-167.Liang ZY, Chen S, He GH, et al. Clinical observation of the application of conbercept preoperatively and intraoperatively assisted to the vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2019, 39(2): 162-167.
72. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2012, 96(4): 587-590. DOI: 10.1136/bjophthalmol-2011-301005.
73. Wei Q, Zhang T, Jiang R, et al. Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy[J]. Invest Ophthalmol Vis Sci, 2017, 58(13): 5783-5791. DOI: 10.1167/iovs.17-22345.
74. Russo A, Longo A, Avitabile T, et al. Incidence and risk factors for tractional macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy[J/OL]. J Clin Med, 2019, 8(11): 1960[2019-11-13]. https://pubmed.ncbi.nlm.nih.gov/31766241/. DOI: 10.3390/jcm8111960.
75. 延艳妮, 魏文斌, 周金琼. 增生性糖尿病视网膜病变围手术期抗VEGF药物使用时机的选择[J]. 国际眼科纵览, 2015, 39(5): 333-336. DOI: 10.3760/cma.j.issn.1673-5803.2015.05.008.Yan YN, Wei WB, Zhou JQ. The using timing of anti·vascular endothelial growth factor at perioperative period for proliferative diabetic retinopathy[J]. Int Rev Ophthalmol, 2015, 39(5): 333-336. DOI: 10.3760/cma.j.issn.1673-5803.2015.05.008.
76. Hu Z, Su Y, Xie P, et al. OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection[J]. Graefe's Arch Clin Exp Ophthalmol, 2019, 257(8): 1611-1619. DOI: 10.1007/s00417-019-04315-0.
77. 冯超逸, 徐格致. 抗血管内皮生长因子药物在糖尿病视网膜病变围手术期的应用[J]. 中国眼耳鼻喉科杂志, 2015, 15(4): 254-257. DOI: 10.14166/j.issn.1671-2420.2015.04.008.Feng CY, Xu GZ. The application of anti-vascular endothelial growth factor drugs in the perioperative period of diabetic retinopathy[J]. Chin J Ophthalmol and Otorhinolaryngol, 2015, 15(4): 254-257. DOI: 10.14166/j.issn.1671-2420.2015.04.008.

Previous Article
Research progress of foveal avascular zone in retinal vascular disease
Next Article
The prosperity and challenge of ocular fundus imaging

Chinese Journal of Ocular Fundus Diseases

New progress in the application of anti-vascular endothelial growth factor drugs in proliferative diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content